Core Viewpoint - LIXTE Biotechnology Holdings, Inc. has initiated a clinical trial combining its compound LB-100 with GSK's immunotherapy Dostarlimab to treat ovarian clear cell cancer, with the first patient dosed at the Lurie Cancer Center [1][2][3]. Group 1: Clinical Trial Details - The clinical trial is led by Dr. Emily M. Hinchcliff at the Lurie Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center [2]. - Patient recruitment is currently underway, and the trial aims to assess the effectiveness of combining LB-100 with Dostarlimab in treating ovarian clear cell carcinoma, which has a high unmet medical need [3]. - The trial was initially launched in January 2024 at The University of Texas MD Anderson Cancer Center, directed by Dr. Amir Jazaeri [3]. Group 2: Company Overview - LIXTE is a clinical-stage pharmaceutical company focused on developing new cancer therapies, with its lead compound LB-100 being a first-in-class PP2A inhibitor [4]. - LB-100 has shown potential to improve outcomes for patients undergoing various chemotherapies or immunotherapies, supported by extensive preclinical data [4]. - The company operates in a unique field of cancer biology known as activation lethality, with a comprehensive patent portfolio protecting its innovations [4].
LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer